Paramyxoviridae Infections - 16 Studies Found Completed : An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection : Parainfluenza : 2013-07-11 : Drug: DAS181-F02 Dry Powder in Bulk Active, not recruiting : A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen : Parainfluenza : 2012-07-17 : Drug: DAS181 dry powder, formulation F02 D Completed : Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants : Human Parainfluenza Virus 2 : 2010-06-07 : Biological: Standard Dose HPIV2 Vaccine Withdrawn : DAS181 in Patients With Parainfluenza : Parainfluenza Infection : 2011-09-24 : Drug: DAS181 20 mg per day of Completed : Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine : Parainfluenza Virus Diseases : 2008-03-05 : Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine Recruiting : A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers : Parainfluenza Respiratory Viral Infections : 2005-09-12 : Biological: Sendai virus vaccine Enders strain; a live, unmodified intranasally administered Sendai viru Completed : Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study : Respiratory Syncytial Virus (RSV) Infection : 2016-03-21 : Drug: BTA-C585 oral capsule Ot Recruiting : Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2017-03-23 : Biological: D46/NS2/N/ΔM2-2-HindIII Recruiting : Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2017-03-28 : Biological: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine Active, not recruiting : A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women : Respiratory Syncytial Virus Infections : 2016-11-03 : Biological: RSV Vaccine (GSK3003891A) formulation 1 Next >>>
